Categories
Solara Active Pharma Sciences Limited — Updates, 15-05-2026: Press Release
15-05-2026 · 01:22 pm
Solara's Q4'26 revenue rose 40% YoY to 391.9 Cr with PAT at 9.6 Cr. Strong base business growth delivered ~26% EBITDA. But the struggling Ibuprofen unit's negative ~17.9 Cr EBITDA led the board to assess strategic options. Debt target ~503 Cr by May.
No comments yet. Be the first to comment!
All announcements from Solara Active Pharma Sciences Limited